Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

7.9K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
7.9K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

688
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
688

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[<sup>18</sup>F]RO948 Tau PET in early and late onset Alzheimer's disease: associations with plasma p-tau 217, atrophy and cognition.

European journal of nuclear medicine and molecular imaging·2026
Same author

Identification of patients receiving amyloid-targeting therapies in observational studies using amyloid PET trajectories: Insights from LEADS.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Tau topography subtypes account for clinical heterogeneity and longitudinal trajectories in early-onset Alzheimer's disease.

Brain communications·2026
Same author

Multimodal axes reveal individualized amyloid- <math><mi>β</mi></math> , tau, and neurodegeneration coupling in aging and Alzheimer's disease.

medRxiv : the preprint server for health sciences·2026
Same author

A plasma protein signature for cerebral amyloid angiopathy.

Acta neuropathologica·2026
Same author

Author Correction: Curing the brain: in search for new astrocyte-specific therapies.

Experimental & molecular medicine·2026

Related Experiment Video

Updated: Mar 7, 2026

Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis
07:45

Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis

Published on: October 25, 2024

859

Tau PET imaging: present and future directions.

Laure Saint-Aubert1, Laetitia Lemoine1, Konstantinos Chiotis1

  • 1Department NVS, Center for Alzheimer Research, Division of Translational Alzheimer Neurobiology, Karolinska Institutet, Novum 5th floor, 141 57, Huddinge, Sweden.

Molecular Neurodegeneration
|February 22, 2017
PubMed
Summary
This summary is machine-generated.

Positron emission tomography (PET) tracers show promise for visualizing abnormal tau protein deposits in the brain, aiding in the diagnosis and monitoring of neurodegenerative diseases like Alzheimer's disease.

Keywords:
BiomarkerClinical researchNeurodegenerative diseasesPositron emission tomography imagingTauTracer development

More Related Videos

High-Resolution Cardiac Positron Emission Tomography/Computed Tomography for Small Animals
11:09

High-Resolution Cardiac Positron Emission Tomography/Computed Tomography for Small Animals

Published on: December 16, 2022

4.4K
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.6K

Related Experiment Videos

Last Updated: Mar 7, 2026

Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis
07:45

Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis

Published on: October 25, 2024

859
High-Resolution Cardiac Positron Emission Tomography/Computed Tomography for Small Animals
11:09

High-Resolution Cardiac Positron Emission Tomography/Computed Tomography for Small Animals

Published on: December 16, 2022

4.4K
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.6K

Area of Science:

  • Neuroscience
  • Molecular Imaging
  • Biomarkers

Background:

  • Abnormal tau aggregation is central to neurodegenerative diseases (tauopathies).
  • The precise role of tau phosphorylation in disease pathogenesis is not fully understood.
  • Targeting in vivo tau deposits is crucial for diagnosis and treatment.

Purpose of the Study:

  • To review recent advancements in tau-specific positron emission tomography (PET) tracers.
  • To discuss the clinical utility and challenges of current tau PET tracers.
  • To suggest future directions for tau PET tracer development and application.

Main Methods:

  • Review of recent scientific literature on tau PET tracers.
  • Analysis of findings from clinical assessments of tracers like THK5317, THK5351, AV-1451, and PBB3.
  • Discussion of the characteristics and limitations of these tracers.

Main Results:

  • Several tau-specific PET tracers (e.g., THK5317, AV-1451) are available for clinical assessment.
  • These tracers enable in vivo visualization of tau pathology in various tauopathies.
  • Challenges remain in fully characterizing tracer binding and utility as early biomarkers.

Conclusions:

  • Tau PET tracers offer potential for discriminating between neurodegenerative diseases and monitoring disease progression.
  • Further research is needed to fully validate the binding properties and clinical utility of tau PET tracers.
  • Optimizing tau PET tracers is essential for early diagnosis and understanding of tauopathies.